by Raynovich Rod | Jun 1, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical...
by Raynovich Rod | May 14, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Biopharmaceutical Stocks- ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a...
by Raynovich Rod | Apr 8, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
4/13 Update Biotech Sector Uptrend Intact XBI at 232.09 Clovis Oncology (CLVS) Up 13% On Upgrade Biotech Sector Brings In Buyers The late Q1 sell-off appears over as buyers are coming in near the 5o day moving average of the XBI, the more volatile ETF.The IBB shows a...
by Raynovich Rod | Mar 12, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Diagnostic Stocks rally with NASDAQ and Small Caps -IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after...
by Raynovich Rod | Mar 2, 2015 | Biopharmaceuticals
Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there”...
by Raynovich Rod | Feb 19, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update...
by Raynovich Rod | Jan 29, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Solid earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous...
by Raynovich Rod | Jan 13, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ and S&P sell off; momentum eases. Mid-cap immuno-oncology stocks : down AGIO, BLUE, EPZM, SGEN.; up CLVS, INCY,...
by Raynovich Rod | Sep 5, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 …Market Continues Sell-Off With QQQs Treading Water in September Follow Technicals on FBT and QQQ. The Federal Reserve continues to be the main concern of investors as the probability of a rate hike looms greater and sooner. Policy officials will meet...
by Raynovich Rod | Aug 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Update 8/20/14 IWM at $115, NASDAQ at 4528 Rayno Focus Stocks Achillion (ACHN) at 52 week high up 204% YTD and 48 % over 30 days. Gilead (GILD) new all time high at $101.36. Rayno Large Cap Biopharmaceuticals Portfolio (ALXN, AMGN, BIIB, FBT, GILD, REGN,RHHBY) up...
